Athena Therapeutics
New Haven
About Athena Therapeutics
Athena Therapeutics developed cutting-edge approaches to probe for, identify, and characterize altered states of NAD metabolism and flux. The Company has recruited a team of researchers with critical expertise in NAD metabolism including Dr. Emmanuel Burgos, formerly of the Albert Einstein College of Medicine, to lead the internal discovery biology capabilities and establish a suite of NAD pathway targets for development. To complement internal expertise, Athena has assembled a Scientific Advisory Board of world experts, which includes Professor Vern Schramm of the Albert Einstein College of Medicine, a world-renown enzymologist specializing in NAMPT and drug design, and Dr. Leonard Post, a seasoned oncology drug developer and discoverer of the PARP inhibitor talazoparib.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Funding stage: Seed
- Last round: Seed (Dec 2020)
- Website: athenatherapeutics.com
- Phone: 1 (203) 200-3672
Industries & Categories
Biotechnology, Health Care, Life Science
Canonical: https://fsome.com/organization/athena-therapeutics-1178489 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.